Trial Profile
The effect of rifaximin on small intestinal motility and microbiota in patients with liver cirrhosis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Mar 2022
Price :
$35
*
At a glance
- Drugs Rifaximin (Primary)
- Indications Hepatic encephalopathy; Liver cirrhosis
- Focus Pharmacodynamics
- 13 Mar 2022 Status changed from recruiting to completed.
- 06 Sep 2017 New trial record